189 related articles for article (PubMed ID: 32961008)
1. Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View.
Felicetti T; Manfroni G; Cecchetti V; Cannalire R
ChemMedChem; 2020 Dec; 15(24):2391-2419. PubMed ID: 32961008
[TBL] [Abstract][Full Text] [Related]
2. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.
Boldescu V; Behnam MAM; Vasilakis N; Klein CD
Nat Rev Drug Discov; 2017 Aug; 16(8):565-586. PubMed ID: 28473729
[TBL] [Abstract][Full Text] [Related]
3. Broad-Spectrum Anti-Flavivirus Activity and Chemistry of Compounds Containing Sulfur and Oxygen Chalcogens.
Sole Burali M; Cecchetti V; Manfroni G
Curr Med Chem; 2023; 30(21):2396-2420. PubMed ID: 35702779
[TBL] [Abstract][Full Text] [Related]
4. Mosquito-Borne Flaviviruses and Current Therapeutic Advances.
Qian X; Qi Z
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746697
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL
Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406
[TBL] [Abstract][Full Text] [Related]
6. Strategies for the identification of inhibitors of West Nile virus and other flaviviruses.
Shi PY
Curr Opin Investig Drugs; 2002 Nov; 3(11):1567-73. PubMed ID: 12476954
[TBL] [Abstract][Full Text] [Related]
7. Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
Li PC; Jang J; Hsia CY; Groomes PV; Lian W; de Wispelaere M; Pitts JD; Wang J; Kwiatkowski N; Gray NS; Yang PL
ACS Infect Dis; 2019 Mar; 5(3):460-472. PubMed ID: 30608640
[TBL] [Abstract][Full Text] [Related]
8. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in flavivirus antiviral drug discovery and vaccine development.
Ray D; Shi PY
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):45-55. PubMed ID: 18221133
[TBL] [Abstract][Full Text] [Related]
10. Flaviviruses are sensitive to inhibition of thymidine synthesis pathways.
Fischer MA; Smith JL; Shum D; Stein DA; Parkins C; Bhinder B; Radu C; Hirsch AJ; Djaballah H; Nelson JA; Früh K
J Virol; 2013 Sep; 87(17):9411-9. PubMed ID: 23824813
[TBL] [Abstract][Full Text] [Related]
11. Broad-Spectrum Small-Molecule Inhibitors Targeting the SAM-Binding Site of Flavivirus NS5 Methyltransferase.
Samrat SK; Bashir Q; Huang Y; Trieshmann CW; Tharappel AM; Zhang R; Chen K; Zheng YG; Li Z; Li H
ACS Infect Dis; 2023 Jul; 9(7):1319-1333. PubMed ID: 37348028
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches to flavivirus drug discovery.
Botting C; Kuhn RJ
Expert Opin Drug Discov; 2012 May; 7(5):417-28. PubMed ID: 22439769
[TBL] [Abstract][Full Text] [Related]
13. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease.
Li Z; Sakamuru S; Huang R; Brecher M; Koetzner CA; Zhang J; Chen H; Qin CF; Zhang QY; Zhou J; Kramer LD; Xia M; Li H
Antiviral Res; 2018 Feb; 150():217-225. PubMed ID: 29288700
[TBL] [Abstract][Full Text] [Related]
14. New developments in flavivirus drug discovery.
Kok WM
Expert Opin Drug Discov; 2016; 11(5):433-45. PubMed ID: 26966889
[TBL] [Abstract][Full Text] [Related]
15. Structure and functionality in flavivirus NS-proteins: perspectives for drug design.
Bollati M; Alvarez K; Assenberg R; Baronti C; Canard B; Cook S; Coutard B; Decroly E; de Lamballerie X; Gould EA; Grard G; Grimes JM; Hilgenfeld R; Jansson AM; Malet H; Mancini EJ; Mastrangelo E; Mattevi A; Milani M; Moureau G; Neyts J; Owens RJ; Ren J; Selisko B; Speroni S; Steuber H; Stuart DI; Unge T; Bolognesi M
Antiviral Res; 2010 Aug; 87(2):125-48. PubMed ID: 19945487
[TBL] [Abstract][Full Text] [Related]
16. Novel Broad Spectrum Inhibitors Targeting the Flavivirus Methyltransferase.
Brecher M; Chen H; Liu B; Banavali NK; Jones SA; Zhang J; Li Z; Kramer LD; Li H
PLoS One; 2015; 10(6):e0130062. PubMed ID: 26098995
[TBL] [Abstract][Full Text] [Related]
17. A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development.
Geiss BJ; Stahla-Beek HJ; Hannah AM; Gari HH; Henderson BR; Saeedi BJ; Keenan SM
J Biomol Screen; 2011 Sep; 16(8):852-61. PubMed ID: 21788392
[TBL] [Abstract][Full Text] [Related]
18. Flavivirus infection-A review of immunopathogenesis, immunological response, and immunodiagnosis.
Chong HY; Leow CY; Abdul Majeed AB; Leow CH
Virus Res; 2019 Dec; 274():197770. PubMed ID: 31626874
[TBL] [Abstract][Full Text] [Related]
19. Strategies Towards Protease Inhibitors for Emerging Flaviviruses.
Nitsche C
Adv Exp Med Biol; 2018; 1062():175-186. PubMed ID: 29845533
[TBL] [Abstract][Full Text] [Related]
20. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs.
Pastorino B; Nougairède A; Wurtz N; Gould E; de Lamballerie X
Antiviral Res; 2010 Sep; 87(3):281-94. PubMed ID: 20452379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
